enVVeno Medical is a late stage clinical med-tech company focused on the development of bioprosthetic (tissue-based) solutions. Co. is developing surgical and non-surgical replacement venous valves for patients suffering from severe Chronic Venous Insufficiency (CVI) of the deep venous system of the leg. Co.'s primary product is the VenoValve®, which is a porcine based replacement venous valve to be surgically implanted in the deep venous system of the leg to treat severe CVI. Co. is also developing a second product called enVVe, which is a non-surgical, transcatheter based replacement venous valve for the treatment of CVI of the deep veins of the leg. The NVNO average annual return since 2018 is shown above.
The Average Annual Return on the NVNO average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether NVNO average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the NVNO average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|